Windlas Biotech Limited
NSE: WINDLAS BSE: WINDLAS
NSE
796.45
7.55 (0.96%)
Prev Close
788.89999
Open Price
792.79999
Volume
77,602
Today Low / High
776.5 / 809
52 WK Low / High
665.1 / 1140
Range
757 - 836
BSE
795.65
7.60 (0.96%)
Prev Close
788.05
Open Price
788.4
Volume
3,252
Today Low / High
778.2 / 804.95
52 WK Low / High
667.3 / 1137.6
Range
756 - 835
The stock is currently trading on both the National Stock Exchange (NSE) and Bombay Stock Exchange (BSE). On the NSE, the stock is priced at 796.45 (target range: 757 - 836), reflecting a change of 7.55001 (0.95703%). On the BSE, it is listed at 795.65 (target range: 756 - 835), showing a change of 7.6 (0.96441%). Both the NSE and BSE data indicate positive movement, suggesting the stock is on an upward trend. This could be an attractive opportunity for investors looking for growth.
05 Jan
792.80
0.46%
02 Jan
797.70
-1.10%
01 Jan
808.80
-0.88%
31 Dec
768.40
3.47%
30 Dec
775.00
0.21%
29 Dec
797.00
-3.24%
26 Dec
800.00
-0.39%
24 Dec
801.00
0.61%
23 Dec
789.45
2.62%
22 Dec
785.00
0.57%
19 Dec
741.00
4.95%
18 Dec
750.00
-1.73%
17 Dec
772.20
-2.84%
16 Dec
789.80
-2.60%
15 Dec
789.80
-1.11%
12 Dec
790.00
-1.01%
11 Dec
784.05
0.76%
10 Dec
749.00
4.05%
09 Dec
759.20
-0.84%
08 Dec
766.00
-1.63%
Windlas Biotech Limited Graph
Windlas Biotech Limited Price Target Predictions: Bullish vs. Bearish Scenarios with Ranges
If you are looking for the target price for Windlas Biotech Limited T1, T2, T3 for both Bullish and Bearish scenarios, here it is. For Bullish: T1, T2, T3. For Bearish: T1, T2, T3. The stock current price is 796.45, with potential price targets ranging from T1, T2, and T3 in both directions based on market conditions.
| Scenario | Price | Target | Range |
|---|---|---|---|
| Bullish Scenario | 795.65 | 803.61 | 723.25 - 883.97 |
| 811.56 | 649.25 - 973.88 | ||
| 819.52 | 573.66 - 1,065.38 | ||
| Bearish Scenario | 795.65 | 787.69 | 708.92 - 866.46 |
| 779.74 | 623.79 - 935.68 | ||
| 771.78 | 540.25 - 1,003.31 |
Overview of Windlas Biotech Limited
ISIN
INE0H5O01029
Industry
Drug Manufacturers - Specialty & Generic
Vol.Avg
44,375
Market Cap
16,687,798,623
Last Dividend
5.8
Official Website
IPO Date
2021-08-16
DCF Diff
278.85
DCF
503
Financial Ratios Every Investor Needs
Stock Dividend of WINDLAS
| Date | Label | Adj Dividend | Dividend | Record Date | Payment Date | Declaration Date |
|---|---|---|---|---|---|---|
| 2025-07-21 | July 21, 25 | 5.8 | 5.8 | 2025-07-21 | 2025-08-27 | |
| 2024-09-17 | September 17, 24 | 5.5 | 5.5 | 2024-09-17 | 2024-10-24 | |
| 2023-09-05 | September 05, 23 | 4 | 4 | 2023-09-05 | 2023-10-12 | |
| 2022-09-09 | September 09, 22 | 3.5 | 3.5 | 2022-09-12 | 2022-10-19 |
Annual Financial Income Report
| Date | Revenue | Co.Rev | GP | GPR | R&D Expenses | G&A Expenses | Operating Income | Net Income | EPS | EBITDA | NIR |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 759.88 Cr | 471.86 Cr | 288.02 Cr | 0.3790 | 6.25 Cr | 3.18 Cr | 66.12 Cr | 60.99 Cr | 29.17 | 112.13 Cr | 0.0803 |
| 2024-03-31 | 628.89 Cr | 400.42 Cr | 228.47 Cr | 0.3633 | 7.88 Cr | 3.74 Cr | 65.22 Cr | 58.19 Cr | 27.97 | 91.64 Cr | 0.0925 |
| 2023-03-31 | 510.58 Cr | 329.58 Cr | 181.01 Cr | 0.3545 | 8.95 Cr | 4.01 Cr | 47.92 Cr | 42.63 Cr | 19.70 | 70.19 Cr | 0.0835 |
| 2022-03-31 | 463.37 Cr | 302.82 Cr | 160.56 Cr | 0.3465 | 6.51 Cr | 4.77 Cr | 40.28 Cr | 38.09 Cr | 18.58 | 59.13 Cr | 0.0822 |
| 2021-03-31 | 426.71 Cr | 274.41 Cr | 152.31 Cr | 0.3569 | 3.61 Cr | 3.55 Cr | 43.41 Cr | 15.83 Cr | 8.69 | 36.17 Cr | 0.0371 |
Annual Financials Balance Sheet
| Date | C&C Equ. | Tot. Assets | Tot. Liab. | Stock. Equity | Tot. Debt | Net Debt | Inv. | PP&E (Net) | Curr. Def. Rev. | Non-Curr. Def. Rev. | LT Invest. | Curr. Liab. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 0.42 Cr | 760.45 Cr | 254.68 Cr | 505.7720 Cr | 32.60 Cr | 32.17 Cr | 81.38 Cr | 221.93 Cr | 0.00 Cr | 0.00 Cr | 0.98 Cr | 249.4430 Cr |
| 2024-03-31 | 5.29 Cr | 626.21 Cr | 176.27 Cr | 449.9360 Cr | 3.64 Cr | -1.65 Cr | 62.19 Cr | 180.29 Cr | 0.00 Cr | 0.00 Cr | 2.00 Cr | 171.7510 Cr |
| 2023-03-31 | 3.69 Cr | 528.98 Cr | 126.70 Cr | 402.2710 Cr | 4.99 Cr | 1.31 Cr | 74.74 Cr | 122.70 Cr | 2.01 Cr | 0.00 Cr | 5.82 Cr | 121.2420 Cr |
| 2022-03-31 | 0.57 Cr | 491.01 Cr | 96.23 Cr | 394.7770 Cr | 6.64 Cr | 6.07 Cr | 58.71 Cr | 98.47 Cr | 0.73 Cr | 0.00 Cr | 2.56 Cr | 93.9860 Cr |
| 2021-03-31 | 15.93 Cr | 296.12 Cr | 97.00 Cr | 199.1190 Cr | 32.35 Cr | 16.42 Cr | 41.46 Cr | 95.67 Cr | 1.48 Cr | 0.00 Cr | 0.00 Cr | 93.4190 Cr |
Annual Financials Cash Flow Statement
| Date | Operating Cash | Investing Cash | Financing Cash | Free Cash | Cash Change | Cash at End | CapEx | Income | Debt Repay | Dividends | Inventory |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 68.1870 Cr | -74.0640 Cr | 1.0130 Cr | 15.9930 Cr | -4.8640 Cr | 0.4240 Cr | -52.1940 Cr | 60.9940 Cr | 27.0080 Cr | -11.4950 Cr | -19.1950 Cr |
| 2024-03-31 | 108.9600 Cr | -92.0680 Cr | -15.2900 Cr | 71.2760 Cr | 1.6020 Cr | 5.2880 Cr | -37.6840 Cr | 58.1870 Cr | -0.3350 Cr | -8.3010 Cr | 12.5490 Cr |
| 2023-03-31 | 60.9650 Cr | -14.1100 Cr | -43.7390 Cr | -9.9250 Cr | 3.1160 Cr | 3.6860 Cr | -70.8900 Cr | 57.0390 Cr | -5.6770 Cr | -7.6280 Cr | -16.0280 Cr |
| 2022-03-31 | 9.1300 Cr | -154.5780 Cr | 130.0880 Cr | -5.6740 Cr | -15.3600 Cr | 0.5700 Cr | -14.8040 Cr | 45.5650 Cr | -25.1950 Cr | 0.0000 Cr | -17.2490 Cr |
| 2021-03-31 | 11.4540 Cr | -20.1980 Cr | 0.7760 Cr | 5.6070 Cr | -2.1480 Cr | 15.9300 Cr | -5.8470 Cr | 21.7400 Cr | 3.8850 Cr | 0.0000 Cr | 10.0700 Cr |
Quarterly Financial Income Report
| Date | Revenue | Co.Rev | GP | GPR | Operating Income | Net Income | EPS | EBITDA | NIR |
|---|---|---|---|---|---|---|---|---|---|
| 2025-09-30 | 222.40 Cr | 136.95 Cr | 85.45 Cr | 0.3842 | 20.96 Cr | 17.80 Cr | 8.48 | 32.20 Cr | 0.0800 |
| 2025-06-30 | 210.09 Cr | 129.73 Cr | 80.36 Cr | 0.3825 | 19.08 Cr | 17.66 Cr | 8.43 | 31.76 Cr | 0.0841 |
| 2025-03-31 | 202.71 Cr | 125.19 Cr | 77.51 Cr | 0.3824 | 17.21 Cr | 16.28 Cr | 7.79 | 30.49 Cr | 0.0803 |
| 2024-12-31 | 195.02 Cr | 120.83 Cr | 74.19 Cr | 0.3804 | 17.69 Cr | 15.58 Cr | 7.45 | 28.74 Cr | 0.0799 |
| 2024-09-30 | 187.00 Cr | 116.43 Cr | 70.57 Cr | 0.3774 | 16.55 Cr | 15.66 Cr | 7.49 | 27.89 Cr | 0.0837 |
Quarterly Financials Balance Sheet
| Date | Cash & Equiv. | Short-Term Inv. | Cash & Short-Term | Net Receivables | Inventory | Total Curr. Assets | PP&E (Net) | Total Assets | Total Liabilities |
|---|---|---|---|---|---|---|---|---|---|
| 2025-09-30 | 0.22 Cr | 261.06 Cr | 261.27 Cr | 197.77 Cr | 70.30 Cr | 563.46 Cr | 234.62 Cr | 814.20 Cr | 280.12 Cr |
| 2025-06-30 | 0.00 Cr | 0.00 Cr | 239.30 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | -505.77 Cr |
| 2025-03-31 | 0.42 Cr | 239.87 Cr | 240.30 Cr | 166.86 Cr | 81.38 Cr | 525.13 Cr | 221.93 Cr | 760.45 Cr | 254.68 Cr |
| 2024-12-31 | 0.00 Cr | 0.00 Cr | 213.02 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | -471.21 Cr |
| 2024-09-30 | 31.45 Cr | 181.57 Cr | 213.02 Cr | 186.83 Cr | 82.01 Cr | 517.20 Cr | 214.71 Cr | 746.89 Cr | 275.69 Cr |
Quarterly Financials Cash Flow Statement
| Date | Net Income | Operating Cash Flow | Investing Cash Flow | Financing Cash Flow | Net Cash Change | Cash at End | Cash at Beginning | CapEx | Free Cash Flow |
|---|---|---|---|---|---|---|---|---|---|
| 2025-06-30 | 17.66 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2025-03-31 | 16.28 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2024-12-31 | 15.58 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2024-09-30 | 15.66 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2024-06-30 | 13.48 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
Splits History
| Date | Label | Split Ratio |
|---|---|---|
| No split history data available. | ||
Similar Stocks: Drug Manufacturers - Specialty & Generic
| Company Name | Symbol | Price | Market Cap | Volume |
|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | SUNPHARMA | ₹1,728.90 | ₹4,148,210,229,633.00 | ₹1,416,681.00 |
| Divi's Laboratories Limited | DIVISLAB | ₹6,363.50 | ₹1,689,309,308,830.00 | ₹145,449.00 |
| Torrent Pharmaceuticals Limited | TORNTPHARM | ₹3,869.80 | ₹1,309,716,163,712.00 | ₹100,222.00 |
| Dr. Reddy's Laboratories Limited | DRREDDY | ₹1,250.00 | ₹1,040,640,656,250.00 | ₹1,184,276.00 |
| Lupin Limited | LUPIN | ₹2,083.70 | ₹951,831,672,062.00 | ₹574,147.00 |
| Zydus Lifesciences Limited | ZYDUSLIFE | ₹921.95 | ₹927,697,427,081.00 | ₹442,181.00 |
| Mankind Pharma Limited | MANKIND | ₹2,195.00 | ₹906,107,133,040.00 | ₹161,264.00 |
| Aurobindo Pharma Limited | AUROPHARMA | ₹1,207.40 | ₹701,259,879,610.00 | ₹644,055.00 |
| Alkem Laboratories Limited | ALKEM | ₹5,552.50 | ₹663,884,662,500.00 | ₹42,044.00 |
| Laurus Labs Limited | LAURUSLABS | ₹1,103.20 | ₹595,569,781,262.00 | ₹1,017,039.00 |
| Glenmark Pharmaceuticals Limited | GLENMARK | ₹2,039.20 | ₹575,463,889,713.00 | ₹333,641.00 |
| Suven Pharmaceuticals Limited | SUVENPHAR | ₹1,078.00 | ₹412,407,234,624.00 | ₹1,177,218.00 |
| Ajanta Pharma Limited | AJANTPHARM | ₹2,912.80 | ₹363,912,485,587.00 | ₹152,336.00 |
| Ipca Laboratories Limited | IPCALAB | ₹1,413.00 | ₹358,484,060,034.00 | ₹118,954.00 |
| J. B. Chemicals & Pharmaceuticals Limited | JBCHEPHARM | ₹1,840.20 | ₹288,269,089,231.00 | ₹131,618.00 |
| Emcure Pharmaceuticals Ltd. | EMCURE | ₹1,489.50 | ₹282,368,298,330.00 | ₹540,896.00 |
| Piramal Enterprises Limited | PEL | ₹1,124.20 | ₹254,856,250,172.00 | ₹2,148,582.00 |
| Wockhardt Limited | WOCKPHARMA | ₹1,452.40 | ₹236,003,626,256.00 | ₹1,876,440.00 |
| AstraZeneca Pharma India Limited | ASTRAZEN | ₹8,438.00 | ₹210,950,000,000.00 | ₹30,842.00 |
| Eris Lifesciences Limited | ERIS | ₹1,542.00 | ₹210,046,445,922.00 | ₹100,879.00 |
| Cohance Lifesciences Limited | COHANCE | ₹513.20 | ₹196,333,456,248.00 | ₹1,497,648.00 |
| Neuland Laboratories Limited | NEULANDLAB | ₹15,040.00 | ₹192,961,530,560.00 | ₹21,999.00 |
| Jubilant Pharmova Limited | JUBLPHARMA | ₹1,070.60 | ₹169,688,424,511.00 | ₹73,556.00 |
| Alembic Pharmaceuticals Limited | APLLTD | ₹837.50 | ₹164,621,616,350.00 | ₹61,314.00 |
| NATCO Pharma Limited | NATCOPHARM | ₹906.10 | ₹162,291,453,207.00 | ₹580,632.00 |
| Granules India Limited | GRANULES | ₹605.25 | ₹146,875,240,359.00 | ₹476,877.00 |
| Caplin Point Laboratories Limited | CAPLIPOINT | ₹1,845.30 | ₹140,264,382,629.00 | ₹55,819.00 |
| Glenmark Life Sciences Limited | GLS | ₹1,086.00 | ₹133,070,838,000.00 | ₹130,938.00 |
| Alivus Life Sciences Ltd. | ALIVUS | ₹898.60 | ₹110,241,459,313.00 | ₹28,862.00 |
| Procter & Gamble Health Limited | PGHL | ₹5,844.00 | ₹97,006,788,408.00 | ₹8,065.00 |
| Strides Pharma Science Limited | STAR | ₹950.65 | ₹87,623,990,564.00 | ₹448,112.00 |
| Akums Drugs & Pharmaceuticals Ltd. | AKUMS | ₹447.35 | ₹68,490,205,646.00 | ₹65,586.00 |
| FDC Limited | FDC | ₹412.90 | ₹67,224,283,684.00 | ₹71,330.00 |
| Aarti Pharmalabs Limited | AARTIPHARM | ₹730.65 | ₹66,231,445,361.00 | ₹112,145.00 |
| Shilpa Medicare Limited | SHILPAMED | ₹317.00 | ₹61,999,435,672.00 | ₹188,272.00 |
| Sequent Scientific Limited | SEQUENT | ₹206.94 | ₹51,698,541,104.00 | ₹527,547.00 |
| Gujarat Themis Biosyn Ltd. | GUJTHEM | ₹425.85 | ₹46,402,858,100.00 | ₹29,002.00 |
| Sun Pharma Advanced Research Company Limited | SPARC | ₹135.34 | ₹43,920,751,720.00 | ₹567,336.00 |
| Innova Captab Limited | INNOVACAP | ₹733.20 | ₹41,957,317,943.00 | ₹22,643.00 |
| Orchid Pharma Limited | ORCHPHARMA | ₹785.20 | ₹39,824,641,246.00 | ₹133,295.00 |
| RPG Life Sciences Limited | RPGLIFE | ₹2,302.00 | ₹38,072,812,530.00 | ₹5,519.00 |
| Aarti Drugs Limited | AARTIDRUGS | ₹404.95 | ₹36,959,786,500.00 | ₹87,551.00 |
| Suven Life Sciences Limited | SUVEN | ₹161.92 | ₹35,688,141,949.00 | ₹189,272.00 |
| Gufic Biosciences Limited | GUFICBIO | ₹332.65 | ₹33,358,975,621.00 | ₹17,408.00 |
| Unichem Laboratories Limited | UNICHEMLAB | ₹433.85 | ₹30,545,534,638.00 | ₹18,863.00 |
Key Executives
Company Secretary & Compliance Officer
Ananta Narayan Panda
Gender: male
Year Born:
Whole-Time Director
Ashok Kumar Windlass
Gender: male
Year Born: 1950
MD & Executive Director
Hitesh Windlass
Gender: male
Year Born: 1977
Joint MD & Executive Director
Manoj Kumar Windlass
Gender: male
Year Born: 1978
President of Sales & Marketing
Mohammed Aslam
Gender: male
Year Born:
Site Quality Head
Om Prakash Sule
Gender: male
Year Born:
Executive Director
Pawan Kumar Sharma
Gender: male
Year Born: 1960
Chief Financial Officer & Chief Executive Officer
Komal Gupta
Gender: female
Year Born:
FAQs about Windlas Biotech Limited
Who is the CEO of the company?
The CEO is Komal Gupta.
What is the current market price of the stock?
The current price is ₹796.45.
What is the 52-week price range?
The range is ₹665.1-1140.
What is the market capitalization of the company?
The market capitalization is ₹1,668.78 crores.
What is the dividend yield?
The dividend yield is 0.73%.
What is the Price-to-Earnings (P/E) ratio?
The P/E ratio is 24.83.
Which sector does the company belong to?
The company operates in the Healthcare sector.
What does the company do?
Overview of Windlas Biotech Limited (ISIN: INE0H5O01029) is a leading Drug Manufacturers - Specialty & Generic in India. With a market capitalization of ₹1,668.78 crores and an average daily volume of 44,375 shares, it operates in the Drug Manufacturers - Specialty & Generic. The company last declared a dividend of ₹5.8.